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Metastatic pulmonary calcification (MPC) is a subdiagnosed metabolic lung disease that is
commonly associated with end-stage renal disease. This interstitial process is characterized
by the deposition of calcium salts predominantly in the alveolar epithelial basement mem-
branes. MPC is seen at autopsy in 60e75% of patients with renal failure. It is often asymptom-
atic, but can potentially progress to respiratory failure. Chest radiographs are frequently
normal or demonstrate confluent or patchy airspace opacities. Three patterns visible on
high-resolution computed tomography have been described: multiple diffuse calcified nodules,
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Metastatic pulmonary calcification 669attenuation parenchymal consolidation. The relative stability of these pulmonary infiltrates, in
contrast to infectious processes, and their resistance to treatment, in the clinical context of
hypercalcemia, are of diagnostic value. Scintigraphy with bone-seeking radionuclides may
demonstrate increased radioactive isotope uptake. The resolution of pulmonary calcification
in chronic renal failure may occur after parathyroidectomy, renal transplantation, or dialysis.
Thus, the early diagnosis of MPC is beneficial. The aim of this review is to describe the main
clinical, pathological, and imaging aspects of MPC.
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Metastatic pulmonary calcification (MPC) is a metabolic
lung disease characterized by the deposition of calcium in
the pulmonary parenchyma. It occurs most often in asso-
ciation with conditions that directly or indirectly result in
hypercalcemia. MPC may be of benign or malignant etiology
[1,2]. Benign causes include chronic renal failure, primary
and secondary hyperparathyroidism, excess exogenous
administration of calcium and vitamin D, sarcoidosis, milk-
alkali syndrome, osteoporosis, and osteitis deformans; the
benign form may also occur following renal or liver trans-
plantation and cardiac surgery. Malignant etiologies include
massive osteolysis from metastases or multiple myeloma,
parathyroid carcinoma, leukemia, lymphoma, breast car-
cinoma, synovial carcinoma, choriocarcinoma, malignant
melanoma, and hypopharyngeal squamous carcinoma
[1,3e9].
Pathological pulmonary calcification can be broadly
divided into metastatic and dystrophic calcifications. MPC
is defined as calcium deposition in normal lung tissue
without prior tissue damage, and is related to chronically
elevated serum calcium-phosphate product. In contrast,
dystrophic calcification requires injured tissue, such as
infected or inflamed lung tissue, even in the absence of
increased serum calcium levels [1,2]. MPC occurs rarely in
patients with normal renal function, normal calcium andphosphate levels, and no underlying pulmonary disease
[10]. The aim of this review is to describe the main clinical,
pathological, and imaging aspects of MPC.Epidemiology
Histological changes of MPC are seen at autopsy in 60e75%
of patients who had previously undergone hemodialysis
[1,11e13]. Benign MPC is known to be a long-term compli-
cation that occurs in patients with chronic renal failure
accompanied by secondary hyperparathyroidism [11]. Pri-
mary hyperparathyroidism infrequently produces metasta-
tic calcification [5]. Among hematological malignancies,
myeloma is the most common cause of cancer-associated
hypercalcemia, seen in 20e30% of cases [14]. MPC occurs
rarely in association with leukemia, although several cases
have been described [7,8,15]. Despite the prevalence of
this condition in patients with renal failure, MPC is rarely
diagnosed antemortem, probably due to the poor sensi-
tivity of standard chest radiographs for the identification of
calcifications [16] and the high frequency of cardiorenal
complications in these patients [17]. Fewer cases of MPC
have been reported recently, suggesting that the incidence
of MPC or visceral calcification is declining [18]. This trend
may be related to improved dialysis techniques [19] and the
widespread use of phosphate binding agents and vitamin D
670 L.C. Bele´m et al.analogs, which allow better control of calcium and phos-
phate levels [20].Figure 1 A 67-year-old man with metastatic pulmonary
calcification. The pathological specimen demonstrates inter-
stitial calcification, appearing as basophilic deposits along the
alveolar septa (hematoxylin & eosin; original magnification,
100).Pathogenesis
MPC is associated most frequently with an increased
calcium-phosphate product as a result of hypercalcemia
and/or hyperphosphatemia. This product is about
40 mg2/dl2 in normal subjects, and metastatic calcifica-
tions are most likely to develop when it exceeds
70 mg2/dl2 [21].
The serum phosphate level is low in primary hyper-
parathyroidism due to the phosphaturic effect of circu-
lating parathyroid hormone (PTH); thus, the calcium-
phosphate product is generally <60 mg2/d12 and metasta-
tic calcification is rarely seen. MPC also occurs rarely in
association with parathyroid carcinoma accompanied by
high serum levels of calcium and PTH [22].
Several factors predispose dialysis patients to the
deposition of calcium salts in the viscera [1]. First, acidosis
in the interdialytic interval has been postulated to leach
calcium from bone, leading to its deposition in soft
tissue during postdialysis alkalosis. Intermittent alkalosis
also increases the activity of alkaline phosphatase, which
catalyzes the release of phosphates. Second, hyperpara-
thyroidism has been shown experimentally to contribute to
pulmonary calcification in the presence and absence of
uremia [1,5]. Third, uremia per se may alter the configu-
ration of tissue proteins, rendering them more calcifiable.
Finally, a reduced glomerular filtration rate causes hyper-
phosphatemia, which in turn elevates the calcium-
phosphate product, favoring crystallization [1,23].
Vitamin D supplementation may contribute to calcifica-
tion, as hypervitaminosis D has been associated with met-
astatic and vascular calcifications [23]. In addition, vitamin
D utilization in dialysis patients may be associated with or
trigger metastatic calcification [24].
Asymptomatic pulmonary calcification is a well-known
complication following orthoptic liver transplantation [4].
Liver transplant recipients receive large amounts of fresh
frozen plasma, which contains sodium citrate, due to the
coagulopathy associated with this procedure. The high
plasma citrate level leads to metabolic alkalosis and hy-
pocalcemia via the chelation of ionized calcium. Para-
thyroid hormone secretion is then triggered and calcium is
deposited in soft tissues following the administration of a
large amount of exogenous calcium [4].
The secretion of free hydrogen ions is an important local
factor in the development of metastatic calcification. The
lung, kidney, and stomach, three of the most frequently
involved organs, are involved in free hydrogen ion secre-
tion. This secretion creates an alkaline environment in
which calcium salts may precipitate [25]. The lung is one of
the primary sites of metastatic calcium deposition in pa-
tients with hypercalcemia [26,27].
MPC or visceral calcification is composed primarily of
whitlockite ([Ca, Mg]3PO4), which appears as an amorphous
substance or as minute crystals, in contrast to the crystal-
line hydroxyapatite more commonly found in vascular
calcification. Lesser amounts of pyrophosphate are also
seen [28].Pathology
Macroscopically, the lungs are diffusely solidified in cases of
MPC. They are heavy, with weights ranging from 590 g to
1800 g. Sectioning reveals irregular or well-delineated
nodules scattered throughout the organ [29].
Microscopically, metastatic calcification has been seen
within the lamina propria of the stomach, in tubules and
interstitium of the kidneys, and in basement membranes of
the epithelium and endothelium of alveoli in the lungs [21].
MPC is an interstitial process [11] characterized by the
deposition of calcium salts predominantly in the alveolar
epithelial basement membranes [11,30], with a particular
affinity for elastic tissue [31]. It can also occur in the
alveolar capillary walls, bronchial walls, and, to a lesser
extent, bronchioles and media of pulmonary arterioles
[11,30]. Regardless of the etiology or organ affected, cal-
cifications appear on hematoxylin and eosin-stained slides
as granular, lamellar, linear, and plate-like basophilic ma-
terials; they also show positivity in Von Kassa and Alizarin
red staining [32,33]. Strong hematoxylin staining in the
alveolar septa (Fig. 1) and the walls of small pulmonary
vessels and bronchi is characteristic of MPC [34,35].
Microscopic examination reveals fibrous widening of the
alveolar septa, with infiltration of these walls by multiple
areas of calcification and a few lymphocytes [29]. The
alveolar lumen is often filled with exudate or calcification,
sometimes surrounded by fibroblast proliferation [29]. A
foreign-body giant cell reaction to the calcium may be
observed [36]. In mild cases, calcium deposits are present
along the alveolar epithelial basement membrane and in
Figure 2 A 42-year-old man with metastatic pulmonary
calcification. A. A scout image from a CT showing confluent
airspace opacities in both upper lobes. CT scan with coronal
reconstructions with (B) lung and (C) mediastinal windows
showing consolidation areas with calcification in the upper
lobes.
Metastatic pulmonary calcification 671alveolar capillary walls without significant desmoplasia or
septal thickening [20]. However, when calcification is se-
vere, a desmoplastic reaction may occur and result in
interstitial fibrosis [11,21,37]. This fibrosis, rather than the
calcium per se, is thought to account for the development
of respiratory symptoms and disturbed pulmonary function
[20].
Clinical manifestations
The clinical manifestations of MPC are usually minimal, but
this condition occasionally causes dyspnea and chronic,
non-productive cough [38]. Because its benign clinical
course, MPC is rarely diagnosed [4]. Although pulmonary
calcification generally progresses slowly and is often
asymptomatic, several reports have described acute res-
piratory insufficiency with a rapidly progressive chest
shadow that mimics pneumonia or pulmonary edema
[26,39,40]. Clinically, the degree of respiratory distress is
often uncorrelated with the degree of macroscopic calci-
fication. Patients with extensive calcification may be
asymptomatic, whereas those with subtle calcification or
normal chest radiographs may have severe respiratory
compromise [41].
Clinical course
MPC usually develops over a long period of time, but it may
occur relatively acutely within several weeks to months
[5,26,39]. In dialysis patients, it is usually related to the
length of survival [42]. Although the factors involved in the
development of the more aggressive form of MPC are not
fully understood, acceleration of the condition has been
previously reported following failed renal transplantation
[1,3] or hypercalcemia [36]. Resolution of pulmonary
calcification in chronic renal failure may occur after para-
thyroidectomy, renal transplantation, or dialysis
[40,43,44]. Spontaneous resolution of changes has also
been described in patients with MPC [31].
Imaging findings
Chest radiographs
Plain-film findings are non-specific [12] and not very useful
for the diagnosis of MPC. Chest radiographs are frequently
normal or demonstrate confluent or patchy airspace opac-
ities (Fig. 2) simulating pulmonary edema or pneumonia
[20,26,31,40,45], despite the exclusively interstitial loca-
tion of calcium pathologically [36]. MPC can also appear as
discrete or confluent calcified nodules or as a diffuse
interstitial process [37,46]. The latter manifestation tends
to occur when calcification is only moderate, and has a
reticular pattern typical of interstitial disease [20]. The
relative stability of these pulmonary infiltrates, in contrast
to infectious processes, and their resistance to treatment
are of diagnostic value [4]. However, as these patients are
highly immunosuppressed, infection should always be
excluded [4]. The density of opacities is not sufficiently
high to suggest calcification in most reported cases, but
672 L.C. Bele´m et al.opacities are massively calcified or become progressively
more dense when left untreated in some cases [47]. The
difficulty of recognizing the calcific nature of these varying
patterns may be explained by the small sizes of calcium
deposits and the currently common use of a high-
kilovoltage and low-contrast technique [38,39,46].
Advanced MPC can be easily recognized on a standard chest
radiograph, but it should be differentiated from other
causes of pulmonary calcification, particularly previous
tuberculous infection [48].
Dual-energy digital chest radiography has been reported
to be more sensitive [20,47,48] and accurate than standard
chest radiography for the detection of MPC [20]. However,
this technique is not widely used [20,47], most likely due to
the availability and advantages of computed tomography
(CT) for the assessment of patients suspected for other
respiratory problems [12].Figure 3 A 40-year-old woman with metastatic pulmonary
calcification. A. High-resolution computed tomography at the
level of the lower lobes shows a consolidation area in the basal
posterior segment of the right inferior lobe associated with a
few small nodules and bilateral ground-glass opacities. B. The
soft-tissue window demonstrates extensive calcification within
the consolidation area and scattered punctate foci of calcifi-
cation. Note also the bilateral pleural effusion.
Figure 4 A 67-year-old man with metastatic pulmonary
calcification (same patient of Fig. 1). High-resolution CT at the
level of the upper lobes shows nodular ground glass opacities in
a predominately centrilobular distribution.Computed tomography
CT, especially high-resolution CT (HRCT), is much more
sensitive than chest radiography [12] in detecting small
amounts of calcification. This modality is increasingly used
in the diagnosis of MPC, thereby obviating the need for
open lung biopsy [3,37]. Whereas calcification is seldom
apparent on radiographs, it is evident on HRCT in approxi-
mately 60% of cases [37].
Changes visible on CT are most marked in the upper
zones of the lungs due to increased alkalinity at the apices,
which encourages the deposition of calcium salts [12]. This
process can be explained by the higher ventilation/perfu-
sion ratio at the apices, which produces a lower partial
pressure of carbon dioxide in arterial blood (PaCO2) and
higher blood pH [1].
Although the infiltrate is histologically interstitial in
nature, the HRCT appearance of MPC can mimic airspace
disease [37,49]. Three patterns of MPC have been described
[47]: multiple diffuse calcified nodules [3,37], diffuse or
patchy areas of ground-glass opacity or consolidation [37],
and confluent high-attenuation parenchymal consolidation
with a predominantly lobar distribution [3] (Figs. 3 and 4).
The distribution of pulmonary calcification can be punc-
tuate within nodular opacities, ring-like, or diffuse,
involving the entire nodule or consolidation area
[31,37,45,47,50]. These findings reflect the deposition of
calcium salts in the alveolar walls around the terminal
bronchioles; thus, the tree-in-bud appearance and bron-
chial wall thickening are not expected in MPC [51]. Inter-
lobular septal thickening is also not observed in MPC;
despite the potential expectation of such thickening due to
the purely interstitial pathological process of MPC, it is
absent because the predominant sites of calcium deposition
seen on pathological examination are the alveolar septa
and, to a lesser extent, the pulmonary arterioles and
bronchioles [37].
The most common parenchymal finding on HRCT is the
presence of centrilobular ground-glass nodular opacities,
with numerous fluffy and poorly defined nodules measuring
3e10 mm in diameter [4,12,30,31,37,45,49]. These opaci-
ties may or may not contain foci of calcification [47]. The
pulmonary nodules are more clearly defined on CT [36]. In
Metastatic pulmonary calcification 673the peripheral region of the secondary pulmonary lobules,
the microchemical environment of the alveoli tends to
become alkalosed in comparison with the central area. The
characteristic distribution of areas of ground-glass attenu-
ation may be explained by the differentiation of the acid-
base balance between the peripheral and central regions
of the secondary pulmonary lobules [52].
More severe interstitial calcification can result in dense
areas of consolidation [31]. Alternatively, multiple lobular
ground-glass opacities [52] or, less commonly, dense
airspace consolidation with a lobar distribution, may be
visible [3,37]. Airspace consolidation is rarely seen [37].
A frequent associated finding is calcification in the ves-
sels of the chest wall [36,37,45,47]. The combination of
pulmonary and vascular calcification is said to be of diag-
nostic value for MPC, narrowing the differential diagnosis of
the causes of pulmonary calcification [37]. In addition to
pulmonary calcification, CT may also reveal extensive
calcification of the myocardium, bronchial walls, small
pulmonary arteries, superior vena cava, and the dura of the
dorsal spine [37]. Soft-tissue window settings are useful to
demonstrate extensive calcification [31].Magnetic resonance imaging
The most common appearance of calcified tissues on mag-
netic resonance imaging (MRI) is a signal void or reduction in
signal intensity [53]. MPC has been shown to appear
hyperintense on T1-weighted images and to have a higher
lesion/muscle signal-intensity ratio on T1-weighted than on
T2-weighted images [53,54]. In the absence of calcification,
lung tissues with thickened and fibrotic alveolar walls should
have higher lesion/muscle MRI signal intensity on proton-
density and T2-weighted images than on T1-weighted im-
ages [53]. The MRI appearance of MPC is unusual and similar
to certain calcified brain lesions that appear hyperintense
on T1-weighted MRI [55,56]. This signal behavior is
explained by a shortening of the T1 relaxation time by a
surface relaxation mechanism. The degree of T1 shortening
is directly related to the surface area of the calcium crystals
[53]. The T1 shortening of water protons in calcified tissues
can be attributed to the surface effects of diamagnetic
calcium particles [53]. Water protons adhering to crystal
surfaces relax more quickly than do those that are distant
from these surfaces [53], although calcium also causes a
change in T2 relaxivity and proton density [56]. The latter
factors reduce MRI signal intensity and nullify any potential
increase in signal intensity caused by T1 shortening [54].
Only in cases in which the microscopic crystal surface area is
very high can the T1 effect predominate, causing a net in-
crease in MRI signal intensity [56]. These MRI signal varia-
tions are directly influenced by the concentration and
surface area of calcium salts [56]. Reductions in hydrogen
proton density and T2 relaxivity cannot overcome the
increased signal intensity caused by T1 shortening [56]. With
calcium concentrations >30e40%, T1-weighted signal in-
tensity declines progressively [56]. The calcium particulates
in MPC may cause a situation in which the effect of T1
shortening overcomes the effects of reduced proton density
and T2 relaxivity; thus, the lesions demonstrate increased
signal intensity on T1-weighted MRI [53].Nuclear medicine
MRI findings are useful for the characterization of calcium
accumulation caused by a metabolic disorder, although
nuclear imaging with technetium-99m-methylene
diphosphonate (Tc99m-MDP) is a more specific and less
expensive method for diagnosis [53]. Radionuclide imaging
is probably the most sensitive technique for the early
detection of MPC [29,48]. Some authors have recommended
the use of scintigraphy as part of the evaluation of dyspnea
in patients with chronic renal failure [4]. Tc99m-MDP is a
labeled organic analog of pyrophosphate that affixes to
hydroxyapatite crystals in bone and calcium crystals in
mitochondria [18]. Tc99m-MDP bone scanning may be used
to detect extraosseous calcification [18]. Despite the af-
finity of MDP for hydroxyapatite, whitlockite also appears
to take up the tracer [1].
Lungs affected by MPC demonstrate increased radioac-
tive isotope uptake. Lung uptake is generally symmetrical
and sufficiently dense to obliterate the rib outlines [28].
Uptake is also commonly seen in the left upper quadrant of
the abdomen and has been attributed to uptake in the
gastric wall [57]. Renal uptake is variable. As renal excre-
tion of pyrophosphate and phosphonate radiopharmaceu-
ticals is a normal finding, the extent of renal uptake in
cases of MPC represents a balance between decreased up-
take due to impaired renal function and increased uptake
secondary to parenchymal calcification [28].
Pulmonary function tests
The findings of pulmonary function tests are usually normal
in patients with MPC [31]. Because alveolar septa are
diffusely involved in MPC, diffusing capacity is decreased.
Anatomical changes due to calcific deposits may lead to a
restrictive syndrome [3,50]. Restrictive and diffusion de-
fects may appear, even when chest radiography appears
normal [11]. Vital capacity has been inversely correlated
with the histological severity of calcification [11]. Patients
may also develop hypoxemia [3,50,58] and die from pro-
gressive respiratory failure. In some cases, respiratory
failure is rapid and acute [59].
Imaging criteria for differential diagnosis
MPC is the most likely cause of multifocal pulmonary
parenchymal calcification in patients with chronic renal
failure. The predilection of calcification for the upper lung
area and its association with calcification in the vessels of
the chest wall may support the diagnosis [60]. The differ-
ential diagnosis of MPC includes conditions that may lead to
diffuse small calcified nodules, diffuse small high-
attenuation non-calcified nodules, and high-attenuation
consolidation [45].
Causes of diffuse small calcified nodules include infec-
tion, pulmonary metastasis, chronic hemorrhagic condi-
tions, occupational and deposition diseases, and idiopathic
disorders such as pulmonary alveolar microlithiasis. These
nodules are most commonly secondary to dystrophic calci-
fication in previously damaged lung parenchyma; they are
frequently seen in patients with healed disseminated
674 L.C. Bele´m et al.histoplasmosis and, rarely, as a sequela of miliary tuber-
culosis. Most of these patients have calcified hilar and/or
mediastinal lymph nodes. Tiny widespread micronodular
calcification is an uncommon sequela of varicella pneu-
monia. Metastatic malignancies that may lead to this
pattern include osteogenic sarcoma, chondrosarcoma,
mucin-producing adenocarcinomas, and thyroid malig-
nancies [2]. It may also occur in treated metastases. Sili-
cosis and coal workers’ pneumoconiosis may have this
aspect and are often associated with egg-shell calcification
of hilar or mediastinal lymph nodes. The nodules are most
prominent in the middle and upper lung zones and may
calcify. Chronic hemorrhagic conditions (hemosiderosis)
may also present as dense centrilobular nodular opacities.
Recurrent episodes of alveolar hemorrhage over several
years are characteristic of this entity. Secondary hemosi-
derosis due to mitral stenosis also may present with small
multifocal calcified nodules. Calcified nodules may also be
seen in accumulations of iron oxide (siderosis), tin oxide
(stannosis), and barium dust (baritosis) in lung macrophages
[45].
The differential diagnosis for diffuse small high-
attenuation noncalcified nodules includes talcosis and
mercury or acrylic cement embolism. Talcosis has been
described in workers exposed to talc and drug abusers
(endovenous administration). Early tomographic manifes-
tations consist of a diffuse micronodular pattern with well-
defined nodules, or diffuse ground-glass opacity. As the
disease progresses, nodule confluence creates hyperdense
consolidations or confluent perihilar masses. Panlobular
emphysema with predominant lower lobe involvement has
been described secondary to the endovenous injection of
Ritalin (methylphenidate). Intravenous mercury injection is
infrequent and most frequently related to attempted sui-
cide and iatrogenic injection. It usually appears on CT as
multiple small metallic spherules scattered diffusely
throughout both lungs. Additional metallic deposits may be
visible in the heart, abdominal vessels, and/or extremities.
Pulmonary embolism caused by acrylic cement is a rare
complication associated with vertebroplasty and may
appear on CT as multiple radiopaque tubular areas of
increased density corresponding to emboli in the segmental
and subsegmental levels of the pulmonary arteries. The
presence of perivertebral leakage contributes to this diag-
nosis [45].
In the presence of high-attenuation parenchymal
consolidation, pulmonary alveolar microlithiasis, amiodar-
one toxicity, talcosis, iodinated oil embolism, and the
aspiration or extravasation of contrast material must be
considered [3,33,45]. The CT findings of amiodarone lung
deposition include septal thickening, interstitial fibrosis,
and high-attenuation focal or multifocal parenchymal
opacities, usually peripheral in location. The association of
dense lung air-space consolidations with high liver and/or
spleen density is of diagnostic value. Iatrogenic causes of
iodinated oil embolism occur after transcatheter oil che-
moembolization or lymphangiography. CT findings consist of
multifocal patchy areas of ground-glass attenuation and
high-attenuation areas of consolidation and collapse. The
characteristic radiographic and HRCT findings of pulmonary
alveolar microlithiasis consist of innumerable bilateral,
tiny, sand-like calcified micronodules. In patients with long-standing disease, the numerous adjacent nodules create
areas of consolidation on CT. Other findings include calci-
fied interlobular septa and small subpleural cysts [33,45].
Treatment
The majority of patients with renal failure and non-
progressive asymptomatic MPC do not require interven-
tion, but treatments have been suggested and used with
some success in patients with symptomatic disease
[1,35,50]. Although the optimal treatment of MPC is not
known, attempts to normalize calcium and phosphate
biochemistry have been the mainstays of therapy [12].
Bisphosphonate has been suggested to normalize calcium in
hypercalcemic patients and to halt the progression of
calcification [35].
Isolated hyperphosphatemia and tertiary hyperparathy-
roidism may also be treated with phosphate binders [9].
Prompt management of secondary and tertiary hyperpara-
thyroidism is necessary to avoid uncontrolled extraskeletal
calcification, ischemic skin necrosis, pruritis, and hyper-
parathyroid bone disease [61]. Therapy with calcium and
vitamin D supplementation is initiated, and para-
thyroidectomy is indicated if the condition is unresponsive
to medical therapy [9].
An increase in the dialysis dose is indicated for patients
with end-stage renal disease [1,58]. Some authors have also
suggested that nocturnal hemodialysis promotes superior
control of the serum phosphate level and uremia compared
withconventionalintermittent (three times weekly) hemo-
dialysis [62]. This technique is promising in delaying the
progression of calcification. Whether the discontinuation of
vitamin D analogs in isolation affects the course of end-
stage renal disease remains unclear, and it may in fact
worsen hyperparathyroidism. However, some authors have
suggested that the discontinuation of vitamin D therapy has
some benefit [58]. Conflicting findings with regard to MPC
following renal transplantation have been published [18];
some authors have reported the improvement or resolution
of visceral calcification, whereas others have reported
dramatic worsening of the disease course [1,36,46].
The aggressive management of acute hypercalcemia
includes the administration of 0.9% saline in combination
with two kinds of osteoclast inhibitor: calcitonin and
bisphosphonate [7]. Galliumnitrate, another potent osteo-
clast inhibitor, may be used if bisphosphonate therapy is
unsuccessful. The somatostatin analog octreotide has been
shown to be effective in the treatment of hypercalcemia of
malignancy due to PTH-related protein secretion [63].
Conclusion
MPC is a frequently asymptomatic and undiagnosed condi-
tion that is commonly associated with end-stage renal dis-
ease. Because it may progress to irreversible lung damage
and respiratory failure, radiologists must be able to
recognize the imaging patterns of this disease. MPC should
be kept in mind when dialysis patients develop unexplained
radiographic changes or pulmonary symptoms. HRCT or
Tc99m-MDP bone scanning can be helpful for diagnosis and
may obviate the need for open lung biopsy.
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